NCT01290861

Brief Summary

The overall objective of this study is to identify a 60 minute cognitive battery, for subsequent use in clinical trials, that detects cognitive deficits in early HD and late pre-manifest HD compared to controls, and that has a potential to show drug induced improvements.

Trial Health

85
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
255

participants targeted

Target at P75+ for all trials

Geographic Reach
4 countries

20 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2011

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

February 4, 2011

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 7, 2011

Completed
Last Updated

August 3, 2012

Status Verified

August 1, 2012

First QC Date

February 4, 2011

Last Update Submit

August 2, 2012

Conditions

Keywords

Huntington's DiseaseCognitive BatteryCognitive TestingCognitionpre-manifest Huntington's Disease

Study Arms (3)

pre-manifest HD

early manifest HD

healthy controls

Eligibility Criteria

Age25 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Study participants will be pre-HD, early stage HD and control subjects. The cognitive tests will be given to all participants. (only varied by order of administration) in order to determine what measures will be best at detecting cognitive changes associated with HD.

You may qualify if:

  • For early HD group, subjects eligible are persons who meet the following criteria:
  • Have clinical diagnostic motor features of HD; and
  • Have huntingtin CAG expansion ≥ 36; and
  • Have Stage 1 or Stage 2 HD, defined as UHDRS TFC scores between 7 and 13 inclusive.
  • For the late pre-manifest HD group, subjects eligible are persons who meet the following criteria:
  • Do not have clinical diagnostic motor features of HD; and
  • Have huntingtin CAG expansion ≥ 39; and
  • Have Burden of Pathology scores ≥ 300 .
  • For the healthy control group, subjects eligible are persons who meet the following criteria:
  • Have no known family history of HD; or,
  • Have known family history of HD but have been tested for the huntingtin CAG expansion and are not at genetic risk for HD (CAG \< 36).
  • For all groups, subjects eligible are persons who meet the following criteria:
  • Are 25 to 55 years of age inclusive;
  • Education at ISCED level 2 or higher, (see Table 5 below) and no known learning disability affecting reading ability, per investigator assessment and judgement;
  • Are capable of complying with study procedures, including cognitive testing that requires spoken, written, and computer based responding;
  • +8 more criteria

You may not qualify if:

  • Current use of investigational drugs or participation in a clinical drug trial (unless approved by the CAB Beta study principal investigator or sponsor);
  • Current intoxication, drug or alcohol abuse or dependence (see below for assessment criteria);
  • Unstable or severe psychiatric disorder, including severe depression as indicated by clinician judgment or IDS-SR score ≥ 39;
  • Significant history of or current medical condition with known or confirmed cognitive sequelae, such as moderate to severe traumatic brain injury, multiple sclerosis, etc;
  • Use of psychostimulants (except caffeine) in the 24 hours prior to site visit;
  • Use of benzodiazepines, alcohol, or other sedating drugs in the 12 hours prior to study visit;
  • If using any psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose over the past 30 days prior to beginning cognitive testing or throughout the study.
  • Drug and Alcohol Use Assessment
  • In the past six months has your alcohol or drug use caused you to miss work (or your educational obligations, if relevant) or created significant conflicts in your personal relationships?
  • Over the past month, how many days would you estimate you have consumed more than 4 standard drinks per day (3 for women)?
  • Over the past month, how many days would you estimate that you have used recreational drugs?
  • Exclude patient if:
  • #1 = YES or
  • #2 + #3= \>18 or
  • Patient appears intoxicated or if an alcohol odour is detected

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (20)

University of California, San Diego

La Jolla, California, 92037, United States

Location

University of California, Los Angeles

Los Angeles, California, 90095, United States

Location

University of California, San Francisco

San Francisco, California, 94117, United States

Location

University of South Florida

Tampa, Florida, 33612, United States

Location

Rush University

Chicago, Illinois, 60612, United States

Location

Hereditary Neurological Disease Center, Inc

Wichita, Kansas, 67206, United States

Location

Albany Medical College

Albany, New York, 12208, United States

Location

Columbia University

New York, New York, 10032, United States

Location

Duke University

Durham, North Carolina, 27705, United States

Location

Wake Forest University Baptist Medical Center

Winston-Salem, North Carolina, 27157, United States

Location

The Ohio State University

Columbus, Ohio, 43210, United States

Location

Oregon Health and Science University

Portland, Oregon, 97239, United States

Location

Monash University/Bethlehem Hospital

Melbourne, Australia

Location

Westmead Hospital

Sydney, Australia

Location

Center for Movement Disorders

Markham, Ontario, L6B 1C9, Canada

Location

Department of Neuropsychiatry

Edgbaston, Birmingham, B15 2FG, United Kingdom

Location

Plymouth Hospitals NHS Trust

Derriford, Plymouth, PL6 8BX, United Kingdom

Location

University Hospital of Wales Cardiff

Cardiff, Wales, United Kingdom

Location

Cambridge Center for Brain Repair

Cambridge, CB2 OPY, United Kingdom

Location

University of Manchester

Manchester, M13 9WL, United Kingdom

Location

Related Links

MeSH Terms

Conditions

Huntington Disease

Condition Hierarchy (Ancestors)

Basal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesDementiaChoreaDyskinesiasMovement DisordersHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesCognition DisordersNeurocognitive DisordersMental Disorders

Study Officials

  • Beth Borowsky, Ph.D.

    CHDI Foundation, Inc.

    PRINCIPAL INVESTIGATOR
  • Julie C Stout, Ph.D.

    Monash University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 4, 2011

First Posted

February 7, 2011

Study Start

February 1, 2011

Last Updated

August 3, 2012

Record last verified: 2012-08

Locations